Jul 2026· Journal of Chemical Information and Modeling· Vol 66, pp. 8522 - 8532· 0 citations· 33 references
Computer ScienceMedicine
TL;DR
The thermodynamic reasons for the increased stability of the G12C mutant in the active, GTP-bound state are quantified and the use of Accelerated Enveloping Distribution Sampling (A-EDS) to efficiently screen a small set of fragments with the strongest binding affinity is explored.
Abstract
Kirsten rat sarcoma virus protein (KRAS) is one of the most important targets in current drug discovery. Its intrinsic properties, including a high structural flexibility and a shallow polar pocket, make KRAS extremely difficult to target. In fact, for a long time it was considered undruggable. A better understanding of its structure and dynamics will help to advance drug discovery efforts. KRAS is a GTPase, which is highly relevant for the growth, proliferation, and differentiation of cells. Several oncogenic mutations have been identified, suggesting that KRAS could be an excellent target in the fight against cancer. In this work, we use molecular dynamics simulations to highlight the challenges of this protein in computational drug design. We start from a characterization of the structural flexibility and the diversity in observed molecular interactions. Then we quantify the thermodynamic reasons for the increased stability of the G12C mutant in the active, GTP-bound state. For this we use two thermodynamic cycles and find that the alchemical mutation leads to internally consistent results, in agreement with the biological observations. Furthermore, we explore the use of Accelerated Enveloping Distribution Sampling (A-EDS) to efficiently screen a small set of fragments with the strongest binding affinity. The screening mode of A-EDS already allows for the identification of the most favorable candidate molecules. Subsequently, further optimization of the A-EDS parameters facilitates a quantification of the relative binding affinities in terms of free energies.
INTRODUCTION/OBJECTIVE
The KRAS G12D mutation is a significant oncogenic factor that promotes cell proliferation and tumor development, particularly in pancreatic cancer. Inhibiting the mutated form of the KRAS protein is a critical strategy in cancer treatment. While molecules like MRTX1133 show promise, the limited e...
Ebru Okutan, Serra Özışık, V. Atalay· Current pharmaceutical desig...· 0 citations
Overall, MD1-MD5 demonstrated excellent binding, structural stability, and pharmacokinetic properties, making them strong candidates for future CDK2-targeted anticancer research.
Dharmesh A. Patel, Apurva Prajapati, Siddharth S. Patel et al.· Biotechnology and applied bi...· 0 citations
The KRAS oncogene, which plays a crucial role in numerous human malignancies, remains a significant challenge. It is amongst the most mutated oncogenes within human cancers, specifically in pancreatic, colorectal, and non-small cell lung cancers, where it is a key driver of cancer initiation and growth. Despite its imp...
Krishna Kalaskar, R. Alavala· Journal of Molecular Graphic...· 0 citations
This work designed and synthesized 20 novel KRAS G12D PROTACs based on the MRTX1133 derivative and found that compound VI-1 exhibited significant KRAS G12D degradation activity in PANC-0203 cells, achieving 69% effective degradation at 10 μM.
Lili Jiang, Wenyan Yang, Yan-Qing Liu et al.· European Journal of Pharmace...· 0 citations
This study harnesses the power of VQE to explore the folding behavior and low-energy conformational landscape of 15 peptides, each comprising eight amino acids, selected from the RCSB Protein Data Bank (PDB).
Ayushi, Madhvi Shakya· The Protein Journal· 0 citations
KRAS is a major oncogenic target in precision oncology because of its conformational flexibility and limited druggability. This study employed an integrated multiscale computational strategy to identify and characterize novel KRAS inhibitors with improved structural, thermodynamic, and electronic stability. Virtual scr...
Vivek Dhar Dwivedi, M. Saeed, Mohammad Amjad Kamal· Journal of Receptor and Sign...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.